The purposes of this amendment were to: • Change the primary objective and primary endpoint to exclude participants who had a clarithromycin- or amoxicillin-resistant strain of H pylori at baseline • Indicate that cytochrome P450 Family 2 Subfamily C Member 19 (CYP2C19) genotyping was optional • Remove wording that allowed a participant's legally acceptable representative as a party capable of giving consent for the study • Clarify that contraception must have been double barrier and that adequate double-barrier contraception must have been used from the signing of informed consent until Day -2 and 2 forms of adequate contraception must have been used from Day -1 until 4 weeks after the last dose of study drug • Allow rescreening of participants with approval from the medical monitor • Clarify that participants who discontinued study drug or withdrew from the study prematurely were to undergo early termination assessments • Redefine noncompliance as taking either less than 75% or more than 120% of study drug during any evaluation period • Exclude the use of cytochrome P450 3A4 (CYP3A4) substrates with a narrow therapeutic index from 14 days prior to Day 1 through the end of treatment • Update the resistance breakpoint for amoxicillin to >0.125 mcg/mL from >0.03 mcg/mL • Add overall study stopping criteria • Remove the requirement for at least 1 dose of study drug to be taken as a condition for inclusion in the MITT analysis set • Add collection of smoking status and alcohol use in the Schedule of Events and to include smoking status, alcohol use, and clinical condition as variables for subgroup analyses • Redefine the 4-week Post-Treatment Period in the Schedule of Events to be Days 42 to 70 • Remove the requirement that the Early Termination Visit be conducted within 14 days of the last dose of study drug being taken • Clarify that ^13C-UBT testing for H pylori infection status should be performed at least 4 weeks after the last dose of study drug

The purposes of this amendment were to: • Add a pre-screen optional fingerstick test to evaluate H pylori status • Clarify that participants must have had a negative urine drug test result for cannabinoids/tetrahydrocannabinol and non-prescribed medications at screening • Add a Week 1 phone call to remind participants about study drug compliance and other assessments • Add the collection of pharmacokinetic samples on Day 15 • Clarify that pretreatment event and AE collection and reporting time windows also included those events considered serious • Clarify that serious AE electronic case report forms (eCRFs) be completed and submitted within 24 hours of the investigator first becoming aware of the serious AE (including serious AEs that were pretreatment events)